Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 79
- Registration Number
- NCT05662319
- Locations
- 🇺🇸
Center for Inherited Blood Disorders (CIBD) Site Number : 8400012, Orange, California, United States
🇺🇸University of California San Diego Site Number : 8400011, San Diego, California, United States
🇺🇸University of Minnesota Site Number : 8400016, Minneapolis, Minnesota, United States
A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
- Conditions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT05649813
- Locations
- 🇰🇼
Investigational Site Number: 01, Kuwait, Kuwait
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 174
- Registration Number
- NCT05630547
- Locations
- 🇧🇪
Investigational Site Number : 0560001, Bruxelles, Belgium
🇧🇬Investigational Site Number : 1000002, Sofia, Bulgaria
🇨🇦Investigational Site Number : 1240002, Ottawa, Ontario, Canada
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
- Conditions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 47885
- Registration Number
- NCT05628090
- Locations
- 🇫🇷
Investigational Site Number :, Chilly-Mazarin, France
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT05624112
- Locations
- 🇨🇳
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital), Guangzhou, Guangdong, China
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 21
- Registration Number
- NCT05607173
- Locations
- 🇧🇬
Investigational Site Number: 100-0001, Sofia, Bulgaria
🇫🇷Investigational site 250-0001, Rennes, France
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
- Conditions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT05607160
- Locations
- 🇩🇪
Investigational site, Germany, Germany
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 182
- Registration Number
- NCT05588843
- Locations
- 🇺🇸
Om Research LLC- Site Number : 8400014, Lancaster, California, United States
🇺🇸BVL Research- Site Number : 8400015, Liberty, Missouri, United States
🇺🇸Gastro One - Germantown- Site Number : 8400002, Germantown, Tennessee, United States
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 285
- Registration Number
- NCT05584670
- Locations
- 🇳🇱
Erasmus MC_Investigational Site Number : 5280003, Rotterdam, Netherlands
🇮🇱Sheba Medical Center - PPDS_Investigational Site Number : 3760003, Ramat Gan, Israel
🇺🇸John Theurer Cancer Center Site Number : 8400001, Hackensack, New Jersey, United States
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT05552859
- Locations
- 🇺🇸
Agile Clinical Research Trials, LLC Site Number: 8400001, Atlanta, Georgia, United States
🇺🇸Emory University Site Number: 8400032, Atlanta, Georgia, United States
🇺🇸Advanced Medical Research Site Number: 8400012, Maumee, Ohio, United States